11β-hydroxylase deficiency epidemiology and demographics: Difference between revisions
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons. 11β-hydroxylase deficiency accounts for 5 percent of all cases of [[congenital adrenal hyperplasia]] and it is considered the second most frequent variant after [[21-hydroxylase deficiency]] | Worldwide, the [[prevalence]] of 11β-hydroxylase deficiency is 1 per 100,000 persons. 11β-hydroxylase deficiency accounts for 5 percent of all cases of [[congenital adrenal hyperplasia]] and it is considered the second most frequent variant after [[21-hydroxylase deficiency]]. The [[incidence]] of 11β-hydroxylase deficiency is 1 per 100,000 persons. Also, this disease is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns. 11β-hydroxylase deficiency affects males and females equally. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
* Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons. | * Worldwide, the [[prevalence]] of 11β-hydroxylase deficiency is 1 per 100,000 persons. | ||
===Incidence=== | ===Incidence=== | ||
* 11β-hydroxylase deficiency accounts for 5 percent of all cases of [[congenital adrenal hyperplasia]] and it is considered the second most frequent variant after [[21-hydroxylase deficiency]] | * 11β-hydroxylase deficiency accounts for 5 percent of all cases of [[congenital adrenal hyperplasia]] and it is considered the second most frequent variant after [[21-hydroxylase deficiency]]. | ||
* Worldwide, the incidence of | * Worldwide, the [[incidence]] of 11β-hydroxylase deficiency is 1 per 100,000 persons. | ||
* 11β-hydroxylase deficiency is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns.<ref name="pmid1554023">{{cite journal| author=Rösler A, Leiberman E, Cohen T| title=High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. | journal=Am J Med Genet | year= 1992 | volume= 42 | issue= 6 | pages= 827-34 | pmid=1554023 | doi=10.1002/ajmg.1320420617 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1554023 }} </ref><ref name="pmid7988480">{{cite journal |vauthors=White PC, Curnow KM, Pascoe L |title=Disorders of steroid 11 beta-hydroxylase isozymes |journal=Endocr. Rev. |volume=15 |issue=4 |pages=421–38 |year=1994 |pmid=7988480 |doi=10.1210/edrv-15-4-421 |url=}}</ref> | * 11β-hydroxylase deficiency is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns.<ref name="pmid1554023">{{cite journal| author=Rösler A, Leiberman E, Cohen T| title=High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. | journal=Am J Med Genet | year= 1992 | volume= 42 | issue= 6 | pages= 827-34 | pmid=1554023 | doi=10.1002/ajmg.1320420617 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1554023 }} </ref><ref name="pmid7988480">{{cite journal |vauthors=White PC, Curnow KM, Pascoe L |title=Disorders of steroid 11 beta-hydroxylase isozymes |journal=Endocr. Rev. |volume=15 |issue=4 |pages=421–38 |year=1994 |pmid=7988480 |doi=10.1210/edrv-15-4-421 |url=}}</ref> | ||
===Gender=== | ===Gender=== | ||
Latest revision as of 14:30, 3 August 2017
|
11β-hydroxylase deficiency Microchapters |
|
Differentiating 11β-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics |
|
FDA on 11β-hydroxylase deficiency epidemiology and demographics |
|
CDC on 11β-hydroxylase deficiency epidemiology and demographics |
|
11β-hydroxylase deficiency epidemiology and demographics in the news |
|
Blogs on 11β-hydroxylase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons. 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency. The incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons. Also, this disease is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns. 11β-hydroxylase deficiency affects males and females equally.
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons.
Incidence
- 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency.
- Worldwide, the incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons.
- 11β-hydroxylase deficiency is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns.[1][2]
Gender
- 11β-hydroxylase deficiency affects males and females equally.
Race
- 11β-hydroxylase deficiency usually affects individuals of the Jewish race.
References
- ↑ Rösler A, Leiberman E, Cohen T (1992). "High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco". Am J Med Genet. 42 (6): 827–34. doi:10.1002/ajmg.1320420617. PMID 1554023.
- ↑ White PC, Curnow KM, Pascoe L (1994). "Disorders of steroid 11 beta-hydroxylase isozymes". Endocr. Rev. 15 (4): 421–38. doi:10.1210/edrv-15-4-421. PMID 7988480.